OverviewChartNewsTraderScreen

UBS Knock-Out IDP/  DE000UM2U146  /

Frankfurt Zert./UBS
2024-05-15  7:41:38 PM Chg.+0.100 Bid9:08:03 PM Ask9:08:03 PM Underlying Strike price Expiration date Option type
0.870EUR +12.99% 0.870
Bid Size: 100,000		 0.890
Ask Size: 100,000		 BIOGEN INC. DL -,000... 141.8024 - 2078-12-31 Call
GlobeNewswire 1:33 AM Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire 05-02 Biogen Reports Progress on Corporate Responsibility Priorities
GlobeNewswire 04-25 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
TeleTrader 04-24 Biogen posts Q1 revenue of $2.3 billion
GlobeNewswire 04-23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 04-02 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
GlobeNewswire 03-06 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire 03-04 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire 02-23 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
TeleTrader 02-13 Biogen's Q4 revenue falls 6% to $2.4 billion
GlobeNewswire 02-12 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
TeleTrader 02-12 Earnings preview: Robinhood, Coinbase and more
GlobeNewswire 02-08 Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire 01-04 Stran & Company Appoints Ian Thomas Wall as Chief Information Officer
GlobeNewswire 2023-12-19 Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire 2023-12-15 CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...
GlobeNewswire 2023-12-14 ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...
TeleTrader 2023-11-08 Biogen's Q3 revenue up 3% to $2.5B
GlobeNewswire 2023-11-06 Biogen Appoints Monish Patolawala to its Board of Directors
GlobeNewswire 2023-10-25 Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study ...
GlobeNewswire 2023-10-25 New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise f...
GlobeNewswire 2023-10-19 Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
GlobeNewswire 2023-09-29 FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
GlobeNewswire 2023-09-26 Biogen Completes Acquisition of Reata Pharmaceuticals
TeleTrader 2023-09-25 Japan approves Eisai-Biogen Alzheimer's drug